LLY

1,120.29

-0.83%↓

JNJ

235.16

-0.31%↓

ABBV

222.63

+0.73%↑

UNH

408.01

-0.62%↓

MRK

115.09

+0.17%↑

LLY

1,120.29

-0.83%↓

JNJ

235.16

-0.31%↓

ABBV

222.63

+0.73%↑

UNH

408.01

-0.62%↓

MRK

115.09

+0.17%↑

LLY

1,120.29

-0.83%↓

JNJ

235.16

-0.31%↓

ABBV

222.63

+0.73%↑

UNH

408.01

-0.62%↓

MRK

115.09

+0.17%↑

LLY

1,120.29

-0.83%↓

JNJ

235.16

-0.31%↓

ABBV

222.63

+0.73%↑

UNH

408.01

-0.62%↓

MRK

115.09

+0.17%↑

LLY

1,120.29

-0.83%↓

JNJ

235.16

-0.31%↓

ABBV

222.63

+0.73%↑

UNH

408.01

-0.62%↓

MRK

115.09

+0.17%↑

Novocure Ltd

Отворен

СекторЗдравеопазване

17.61

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

17.4

Максимум

17.86

Ключови измерители

By Trading Economics

Приходи

-47M

-71M

Продажби

-295K

174M

EPS

-0.62

Марж на печалбата

-40.871

Служители

1,605

EBITDA

-29M

-63M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+46.23% upside

Дивиденти

By Acuity

Следващи печалби

23.07.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

506M

2B

Предишно отваряне

17.61

Предишно затваряне

17.61

Настроения в новините

By Acuity

50%

50%

162 / 342 Класиране в Healthcare

Novocure Ltd Графика

Миналото представяне не гарантира бъдещи резултати.

Относно Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
help-icon Live chat